Concepedia
Author
Tina Kurent
Also Known As
Kurent, Tina, T Kurent, Tina Kurent
21
Publications
274
Citations
7
H-Index
3
Concepts
All Affiliations
1
51
2
×
All Concepts
258
Endoscopic Postoperative Recurrence in Crohn’s Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study
Henit Yanai, A Kagramanova, O. V. Knyazev, +68
Journal of Crohn s and Colitis
2022
59
Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn’s Disease Likely to Achieve Endoscopic and Biochemical Remission
Jurij Hanžel, Jurij Zdovc, Tina Kurent, +12
Clinical Gastroenterology and Hepatology
ImmunologyGastroenterologyBiochemical RemissionAchieve EndoscopicClinical Gastroenterology +3
2020
Success and safety of high infliximab trough levels in inflammatory bowel disease
David Drobne, Tina Kurent, Saša Golob, +18
Scandinavian Journal of Gastroenterology
2018
46
Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease
David Drobne, Tina Kurent, Saša Golob, +8
Alimentary Pharmacology & Therapeutics
2019
40
Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease
Jurij Hanžel, Nejc Sever, Ivan Ferkolj, +9
United European Gastroenterology Journal
27
Ustekinumab Dosing Individualization in Crohn’s Disease Guided by a Population Pharmacokinetic–Pharmacodynamic Model
Jurij Zdovc, Jurij Hanžel, Tina Kurent, +11
Pharmaceutics
2021
24
Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed label
S Stefanović, Iris Detrez, Griet Compernolle, +10
European Journal of Gastroenterology & Hepatology
11
Page 1